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Background: Numerous pen devices are available to administer recombinant Human Growth Hormone (rhGH),
and both patients and health plans have varying issues to consider when selecting a particular product and device
for daily use. Therefore, the present study utilized multi-dimensional product analysis to assess potential time
involvement, required weekly administration steps, and utilization costs relative to daily rhGH administration.
Methods: Study objectives were to conduct 1) Time-and-Motion (TM) simulations in a randomized block design
that allowed time and steps comparisons related to rhGH preparation, administration and storage, and 2) a Cost
Minimization Analysis (CMA) relative to opportunity and supply costs. Nurses naïve to rhGH administration and
devices were recruited to evaluate four rhGH pen devices (2 in liquid form, 2 requiring reconstitution) via TM
simulations. Five videotaped and timed trials for each product were evaluated based on: 1) Learning (initial use
instructions), 2) Preparation (arrange device for use), 3) Administration (actual simulation manikin injection), and 4)
Storage (maintain product viability between doses), in addition to assessment of steps required for weekly use. The
CMA applied micro-costing techniques related to opportunity costs for caregivers (categorized as wages), non-drug
medical supplies, and drug product costs.
Results: Norditropin® NordiFlex and Norditropin® NordiPen (NNF and NNP, Novo Nordisk, Inc., Bagsværd, Denmark)
took less weekly Total Time (p < 0.05) to use than either of the comparator products, Genotropin® Pen (GTP, Pfizer,
Inc, New York, New York) or HumatroPen® (HTP, Eli Lilly and Company, Indianapolis, Indiana). Time savings were
directly related to differences in new package Preparation times (NNF (1.35 minutes), NNP (2.48 minutes) GTP (4.11
minutes), HTP (8.64 minutes), p < 0.05)). Administration and Storage times were not statistically different. NNF (15.8
minutes) and NNP (16.2 minutes) also took less time to Learn than HTP (24.0 minutes) and GTP (26.0 minutes), p <
0.05). The number of weekly required administration steps was also least with NNF and NNP. Opportunity cost
savings were greater in devices that were easier to prepare for use; GTP represented an 11.8% drug product
savings over NNF, NNP and HTP at time of study. Overall supply costs represented <1% of drug costs for all
devices.
Conclusions: Time-and-motion simulation data used to support a micro-cost analysis demonstrated that the pen
device with the greater time demand has highest net costs.
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Injectable human growth hormone (hGH) has been in
use since the late 1950s for treatment of pediatric and
adult patients with growth hormone deficiency [1,2].
Traditionally, hGH formulations required reconstitution
of lyophilized powder and transfer from vial to syringe
prior to intramuscular administration. The first recom-
binant somatropin (somatropin [rDNA origin], or
rhGH) was approved in 1985 by the United States (US)
Food and Drug Administration,
2 and liquid formulations
of rhGH (Nutropin AQ® and Norditropin SimpleXx®)
became available in the mid-late 1990s [3-5]. Largely
due to pediatric use of rhGH and potential fear of syr-
inges and needles in this population [1], manufacturers
began to improve subcutaneous administration methods
via administration device development.
Similar to patients diagnosed with Type 1 diabetes
who require daily insulin replacement, rhGH must also
be administered daily in order to achieve maximum
therapeutic effect. Therefore, application of insulin
injection devices to rhGH administration was pursued
[6]. The first insulin pen injector, NovoPen,® was intro-
duced in 1985, with subsequent development and
release of the prefilled, disposable FlexPen® insulin
device [7]. Liquid formulation of rhGH in the United
States initially consisted of a liquid-based product in a
vial (Nutropin AQ® 10 mg vials) but eventually a Nutro-
pin AQ® pen device with liquid formulation of rhGH
was introduced to the US market. Other pen devices
were developed, including application of the insulin-
based NovoPen® and FlexPen® technologies to rhGH
administration with the Norditropin NordiPen® (pre-
mixed, pre-filled rhGH cartridges) and Norditropin
NordiFlex® (pre-mixed, pre-filled disposable rhGH
injection device) [8].
Published patient preference studies of insulin injection
devices have also guided development of rhGH adminis-
tration injection devices [9,10]. Recent evaluations of
patient preferences for rhGH injection devices indicated
that patients valued “ease of use” [11] and device charac-
teristics such as “r e l i a b i l i t y ,e a s eo fu s e ,l a c ko fp a i nd u r -
ing injection, safety on use and in storage, and the
number of steps in preparation before use, during use
and after” [12] as the most important attributes when
selecting a device for rhGH replacement therapy.
Substitution of one product for another where more
than one product choice is available may not always be
useful or recommended for biologically engineered
(biosimilar) medications [13]. In addition, product price
alone is not always the best discriminator with regard to
pharmacy formulary decision-making, and pharmacy
benefit managers are creating new ways of managing
costs relative to specialty pharmaceutical products [14].
Although evidence-based clinical guidelines should be
the main consideration when selecting treatment
options, a product’s “ease of use” characteristics should
also be considered. Ease of use characteristics become
especially important with regard to rhGH, which must
be either parent-administered (in the case of small chil-
dren) or self-administered once a day in the evening,
often for several years or more. Medication compliance
may also be impacted relative to preparation, adminis-
tration and ease of use characteristics [11,12]. For
patients (and parents of patients) learning to safely
administer rhGH, product ease of use characteristics
also become important in allowing training to take place
in as short a period of time as possible. Therefore, the
present study was conducted in order to evaluate these
characteristics relative to four locally available rhGH
products.
Methods
The present study evaluated the number of steps, poten-
tial time involvement relative to learning to administer
rhGH, and utilization costs (opportunity costs, non-drug
supply costs and drug costs) of daily rhGH administra-
tion via four rhGH pen devices listed in Table 1. At the
time of the study, Norditropin NordiFlex® (NNF, Novo
Nordisk, Inc., Bagsværd, Denmark) [8] was the only pre-
filled, pre-mixed disposable pen available. The Norditro-
pin NordiPen® (NNP, Novo Nordisk, Inc., Bagsværd,
Denmark) [8] was also available as a ready-to-administer
pre-filled liquid cartridge, and neither product required
reconstitution prior to use. The Genotropin® Pen (GTP,
P f i z e r ,I n c ,N e wY o r k ,N e wY o r k )[ 1 5 ]a n dH u m a t r o -
Pen® (HTP, Eli Lilly and Company, Indianapolis, Indi-
ana) [16] pen devices were selected for comparison
based on local availability at the time of the study and
because reconstitution was required (Table 2). Prior to
the study, the Norditropin NordiFlex® pen was believed
to be faster to use and easier to prepare for administra-
tion because of the pre-mixed, pre-filled, disposable
nature of the device.
A simulated Time-and-Motion (TM) analysis was
designed based on standard industrial engineering tech-
niques [17,18] in order to determine the potential
amount of patient/parent time required to Learn (initial
instructions for use), Prepare (arrange device for use),
Administer the dose to a simulated child [19] (actual
injection), and Store (provide for product viability
between doses) each of the four devices and assess the
complexity involved with the use of each device
(Figure 1). Although the ideal study would have evalu-
ated actual patient and/or parental learning relative to
each device, nurses were recruited to participate in the
study as described below.
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Resource Center (LRC) was utilized for the TM simula-
tions, because the laboratory possesses state-of-the-art
practice simulation areas that are used to train students.
Six registered nurses who had prior experience giving
subcutaneous injections but were naïve to rhGH admin-
istration and the pen injection devices were recruited by
word of mouth. The simulation room setup consisted of:
￿ a Learning station with a computer and print
materials pertinent to all of the devices under study;
￿ a medication Preparation station with all devices
and supplies necessary for medication preparation
and administration;
￿ an Administration station with a child size manikin
[19] for actual medication administration lying on a
hospital bed; and
￿ a Storage station consisting of a table for medica-
tion to be set upon ("stored”)b e t w e e nf i r s ta n d
second simulation doses.
The distance from the Learning station to the other
stations was approximately 6 feet, with only 4 steps
required to move between each of the other stations.
The order of pen device simulations was randomized by
product across participants (randomized block design),
so that bias against one device based on learning
accrued from using another device was minimized.
At the beginning of each set of pen device simulation
trials, participants were given manufacturer instructional
materials that were intended for use by patients and
families (see Table 1). Instructional materials for NNF
consisted of an instructional DVD provided as part of a
patient starter kit. For NNP, GTP and HTP, instruc-
tional videos were available via the internet. Learning
materials were only reviewed once by participants prior
to proceeding to the medication Preparation station,
although instructional materials remained available in
case of additional questions.
Each trial consisted of first dose (Dose 1) preparation
of the pen device including reconstitution if required,
administration of a dose to the manikin, and storage of
the device. This was followed by a second dose (Dose 2)
using the pen device prepared as part of the Dose 1
simulation. Participants retrieved the pen device from
the Storage station, brought it to the Preparation station,
attached a new needle to the pen, and administered
Dose 2 to the manikin. Because activities related to pre-
paration and administration of Dose 2 were assumed to
be the same once Dose 1 preparation was completed, all
simulations were conducted and analyzed based on the
steps a parent would complete in order to administer
Dose 1 and Dose 2 of each pen device. Dose 2 was also
conceived as being identical in steps and character to
preparation, administration, and storage methods that
w o u l db eu s e db yap a r e n tu n t i lp r e p a r a t i o no fan e w
pen device would become necessary. Then Dose 1 and
subsequent doses would be administered from the new
pen device. Five iterations of each Dose 1 and Dose 2
simulation were completed for each pen device in a
Table 1 Evaluated Products and Devices








(NNP) 5 mg CRT
Novo Nordisk Disposable, pre-filled cartridges to be inserted into re-usable NordiPen dial-a-dose injection pens
http://www.norditropin-us.com/parents/nordipen.asp
Genotropin® Pen
(GTP) 5.8 mg PFS
CRT
Pfizer Intra-Mix 2-chamber cartridge attached to Genotropin® Pen 5
http://www.genotropin.com/content/Resources_video_guide_ch.aspx
HumatroPen®
(HTP) 6 mg CRT
Eli Lilly Cartridge reconstitution kit (lyophilized powder in cartridge with separate diluent in pre-filled diluent syringe);
reconstituted cartridge attached to HumatroPen®
http://www.humatrope.com/common_pages/flash/index.html
Table 2 Cost and Product Reconstitution Method by Device
Drug & Device WAC
a $/mg Reconstitution Method Final Concentration Injection Amount
NNF $52.65 Provided in liquid form 5 mg/1.5 ml Dial to 0.6 mg on device
NNP $52.65 Provided in liquid form 5 mg/1.5 ml Dial to 0.6 mg on device
GTP $46.42 Two-chamber cartridge 5 mg/ml Dial to 0.6 mg on device
HTP $52.65 Infuse powder in cartridge with diluent from pre-filled syringe 2.08 mg/ml Dial to 0.6 mg on device
aUS Wholesale Acquisition Cost (WAC) as of February 2009
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observations (30 observations each Dose 1 and Dose 2)
across the six simulation participants.
Dosages used during simulations were based on a 4.2
mg/week average dose [2], resulting in a 0.6 mg daily
dose for a 6 year old girl weighing 20 kg (50
th percentile
weight based on US standards) [20]. Non-drug (medical)
supplies required as part of the administration process
were also quantified. All simulation sessions were video-
taped and timed; analysis was completed by project
staff. Statistical analysis was completed using descriptive
statistics at an ap r i o r isignificance level of 0.05. Since
the primary purpose of the evaluation was to compare
use of NNF relative to NNP, GTP and HTP, all time
comparisons were completed relative to the NNF pen
device and evaluated using one-way analysis of variance
(ANOVA) for repeated measures design. A Tukey test
post hoc analysis of results was conducted to determine
where time differences occurred if present. Tapes and
manufacturer supplied educational materials were also
assessed in order to count the number of steps required
to Prepare, Administer, and Store each pen device.
A Cost Minimization Analysis (CMA) using micro-
cost methods [21,22] was conducted to determine
potential time and supplies cost savings through the use
of one pen device over another. All US minimum wage
labor cost information [23] and Wholesale Acquisition
Cost (WAC) price information for each of the four
rhGH drug products [24] was collected from a nation-
ally available database, while non-drug medical supply
Figure 1 Simulation scenario based on administration of recombinant Human Growth Hormone (rhGH) to simulated 50
th percentile
weight 6 year old girl.
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dages) were derived from a nationally available nursing
supplies catalog [25]. The entire study was classified as
“Minimal Risk” by the University of Utah Institutional
Review Board, and all nurse participants signed
Informed Consent forms to that effect.
Results and Discussion
Time-and-Motion (TM) Simulation Results
The order of pen device simulations and evaluation of
products listed in Table 1 was conducted in a rando-
mized block design in order to minimize learning trans-
fer from one device to the next. Each of 6 participants
completed 5 simulations for the 4 pen devices resulting
in a total number of 30 observations each for first (Dose
1) and second (Dose 2) doses of each pen device (total
of 60 observations per pen device). As outlined in Figure
1 and based on learning theory [26], participants were
estimated to become “experts” in using the devices after
preparing and administering two doses 5 times each.
Four variables were assessed (Learning, Preparation,
Administration, and Storage) as part of a multi-dimen-
sional analysis of the rhGH pen devices.
The Learning variable was assessed based on the length
of time taken by participants to review manufacturer pro-
vided DVD and internet-based video materials one time,
and results are listed in Table 3. The amount of time
required to learn to use the NNF, NNP and HTP devices
were statistically different from GTP (p < 0.05). Learning
variable time results ranged from a low of 7 minutes
(NNP manufacturer internet instructions) to a high of 33
minutes (HTP manufacturer internet instructions),
although average Learning times ranged from 15.8 min-
utes (NNF) to an average of 26.0 minutes (GTP).
The remaining results from Preparation, Administra-
tion, and Storage analysis of the TM simulations are
listed in Additional File 1, Table S1. In terms of average
Dose 1 Preparation times, NNP (2.48 minutes) GTP
(4.11 minutes), and HTP (8.64 minutes) were all signifi-
cantly different from NNF (1.35 minutes, p < 0.05).
With regard to GTP and HTP which both require
reconstitution prior to use, the results were not surpris-
ing. The Dose 1 Preparation time differences between
NNF and NNP are likely due to the additional NNP
step requirement to insert an already liquefied rhGH
cartridge into the NNP pen device, a step not required
i nt h er e a d y - t o - u s ed i s p o s a ble NNF pen device. Dose 2
preparation times were noticeably faster than Dose 1
preparation times, with only average GTP time (1.30
minutes) evaluated as significantly different than NNF
(0.86 minutes), NNP (0.92 minutes), and HTP (0.94
minutes) average Dose 2 preparation times. Once pre-
pared for use, no significant differences were seen in
Administration time between the pen devices (all device
Dose 1 ranges 0.63-0.68 minutes; all device Dose 2
ranges 0.56-0.63 minutes). Only GTP was significantly
different (p < 0.05) with regard to Storage, regardless of
whether either Dose 1 or Dose 2 were being stored for
the next administration.
Overall and on average, NNF (Dose 1 = 2.33 minutes;
Dose 2 = 1.75 minutes) and NNP (Dose 1 = 3.61 min-
utes, p < 0.05, Dose 2 = 1.94 minutes) took less Total
Time than HTP (Dose 1 = 9.77 minutes, p < 0.05, Dose
2 = 1.95 minutes) and GTP (Dose 1 = 5.46 minutes,
p < 0.05, Dose 2 = 2.45 minutes, p < 0.05) primarily due
to differences in Preparation time (p < 0.05). Users
became more efficient in performing each step with
practice (i.e., took less time to perform) and individual
Total Times decreased for each participant with each
succeeding trial of each pen device (p < 0.05).
Process flow diagrams (Figures 2 and 3) were created
based on manufacturer supplied patient instructions for
each pen device. Figure 2 outlines manufacturer sug-
gested usage steps common to all pens, while Figure 3
outlines additional manufacturer suggested preparation
steps that were required of the NNP, GTP, and HTP
pens beyond that of the NNF pen. Of note, only the
manufacturer instructions for HTP [16] asked users to
check an expiration date, although best practices dictate
checking expiration dates of all medicines.
Differences between pens identified in both the pro-
cess flow charts and the TM analysis results were also
reinforced in the results of the Step Analysis (Additional
File 1, Table S2). The combined number of steps out-
lined in Figure 2 and Figure 3 process flow charts indi-
cate that the number of preparation steps for GTP (20
steps) and HTP (27 steps) were nearly double those
required by NNF (11 steps) and NNP (15 steps).
Although the total number of steps that must be com-
pleted on a weekly basis in order to administer a daily
dose are not dramatically different (low of 175 steps for
NNF and 179 steps for NNP to high of 185 steps for
GTP and 186 steps for HTP), the NNF and NNP
devices require less preparation manipulation due to the
availability for users of rhGH in a liquid, ready-to-use
form. Even the small number of required additional pre-
paration steps necessary for use of GTP and HTP are
relatively time consuming (p < 0.05 relative to NNF).
Table 3 Time Differences in Learning to Use Devices
Drug & Device Learning Time (mins)
Average (s.d.) Range 95% C.I.
NNF 15.83 (2.86) 12.00 - 21.00 12.83 - 18.83
NNP 16.17 (8.35) 7.00 - 28.00 7.40 - 24.93
GTP 26.00* (4.77) 19.00 - 32.00 20.99 - 31.01
HTP 24.00 (8.29) 15.00 - 33.00 15.30 - 32.71
*p < 0.05 relative to NNF; N = 6 trials
Nickman et al. BMC Nursing 2010, 9:6
http://www.biomedcentral.com/1472-6955/9/6
Page 5 of 9Figure 2 Process flow diagram of common manufacturer instructions and time-and-motion simulation steps associated with use of
studied recombinant Human Growth Hormone (rhGH) pens.
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CMA results from the micro-cost analysis are listed in
Additional File 1, Table S3. The estimated weekly Total
T i m e st h a tr e s u l t e df r o mt h eT Mp o r t i o no ft h em u l t i -
dimensional analysis were used to estimate required
potential patient/parental time necessary for daily rhGH
administration. Weekly times were then valued as
opportunity costs [22] and valued using a United States
minimum wage value of $6.55 per hour [23]. Minimum
wage versus other wage estimates was utilized given that
such relatively small time requirements for daily and
weekly administration would not require a parent or
young adult to miss work in order to administer to
either a child or self, and it is highly unlikely that skilled
care providers would be brought into the home for daily
rhGH administration. Opportunity cost savings, albeit
small at $1,100 or less per year, were greatest with those
pen devices that were easier to prepare for use, espe-
cially when multiple doses, and hence preparatory activ-
ities, must be made on a weekly basis. Weekly non-drug
medical supply costs (needles, alcohol sponges, dry
sponges, and bandages) represented less than 1% of
drug costs for all devices. Although not insignificant on
a yearly basis, cost differences between required supplies
for the 4 comparator pen devices were relatively small.
WAC price estimates used to calculate the opportunity
cost savings relative to selection of one product over
a n o t h e rw e r eo n l yd i f f e r e n tf o rG T P ,r e p r e s e n t i n ga n
11.8% opportunity cost savings over NNF, NNP and
HTP at the time of this study. Since contracting dis-
counts and tiered pricing strategies might be utilized by
benefit managers in actual practice, drug price compari-
sons should be performed on an individual basis to
assess potential savings [13,14].
Previous research has documented that patients desire
rhGH administration devices that are easy to use,
require less steps for successful administration, and pro-
vide the opportunity for improved compliance with daily
therapy [12]. Benefit managers are also recognizing that
improved clinical outcomes may be related in some
measure to medication administration methods [14],
leading to the consideration of pen devices such as
those evaluated in this study. In addition, device func-
tion factors such as number of steps required for admin-
istration that potentially impact safe and accurate use
should also be considered [27]. Devices that require
Figure 3 Pen-specific additional manufacturer instructions and preparation steps required for use beyond those listed in Figure 2.
Nickman et al. BMC Nursing 2010, 9:6
http://www.biomedcentral.com/1472-6955/9/6
Page 7 of 9fewer steps may lead to reductions in dosing errors.
Although safety per se was not evaluated in the present
study, device and medication regimen factors such as
simplicity should be considered when primary usage is
geared toward lay population users [12,28-30]. In order
for parents to administer rhGH in the home, patients/
parents need to learn to prepare, administer and store
rhGH, in addition to learning to perform injections in
an accurate and reliable manner. If devices are easier for
patients and caregivers to learn and use, it may also be
easier for them to be adherent to medication regimens.
Limitations
Nurses served as consenting participants in this study.
Although participants were not representative of an
“average” patient or parent who is likely to be unfamiliar
with injection administration techniques, nurse partici-
pants were unfamiliar with rhGH administration in gen-
eral, and naïve to the four comparator pen devices.
In addition, only 6 nurses participated in the study.
Statistical power at the 0.05 level required a minimum
of 30 observations per device, and the study was
designed to maximize observations (30 observations
each for Dose 1 and Dose 2) while minimizing purchase
and wastage relative to study product costs.
Finally, micro-cost and cost minimization analyses are
dependent upon local and regional cost variations for
drugs and non-drug medical supplies, which may also
differ from global costs. However, analyses modelling for-
mulae allow for cost substitutions based upon local rates.
Conclusions
NNF and NNP took less Total Time vs. GTP and HTP
due to a shorter amount of time needed to learn and
prepare rhGH for daily administration. Time-and-
motion simulation data used to support a micro-cost
analysis also demonstrated the value of multi-dimen-
sional product-device analysis.
Additional file 1: Additional File 1, Table S1 - Time Differences in
Weekly Preparation, Administration & Storage. Results of time-and-
motion analysis for Preparation, Administration & Storage variables
Additional file 2: Additional File 1, Table S2 - Step Differences in
Weekly Preparation, Administration & Storage. Results of step analysis
for Preparation, Administration & Storage variables
Additional file 3: Additional File 1, Table S3 - Opportunity and
Supplies Cost Differences in Weekly and Yearly Preparation,
Administration & Storage. Results of time and supplies opportunity
cost analysis for Preparation, Administration & Storage variables on a
weekly and yearly basis
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